{"id":"NCT02550197","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","officialTitle":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 18 to 60 Years in the Republic of Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2016-04","completion":"2016-07","firstPosted":"2015-09-15","resultsPosted":"2016-11-04","lastUpdate":"2022-03-28"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016","otherNames":[]},{"type":"BIOLOGICAL","name":"Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation","otherNames":[]}],"arms":[{"label":"QIV Group","type":"EXPERIMENTAL"},{"label":"TIV Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern Hemisphere (NH) 2015 2016 seasonal formulations, in subjects aged 18 to 60 years in the Republic of Korea for the registration of the QIV by the Ministry of Food and Drug Safety.\n\nObjectives:\n\n* To evaluate the immunogenicity of QIV and TIV (split-virion, inactivated) NH 2015-2016 seasonal formulations. The compliance, in terms of immunogenicity, of the QIV NH 2015-2016 formulation, with the requirements of the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96 will be assessed.\n* To evaluate the safety profile of QIV and TIV (split-virion, inactivated) NH 2015-2016 seasonal formulations","primaryOutcome":{"measure":"Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route","timeFrame":"Day 0 (pre-vaccination) and Day 21 post-vaccination","effectByArm":[{"arm":"Quadrivalent Influenza Vaccine Group","deltaMin":142,"sd":null},{"arm":"Trivalent Influenza Vaccine Group","deltaMin":116,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":5,"countries":["South Korea"]},"refs":{"pmids":["28933625"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":200},"commonTop":["Injection site Pain","Myalgia","Malaise","Headache","Shivering"]}}